Biomarker-Integrated Umbrella, Advanced Gastric Cancer

In-depth understanding of molecular characteristics of gastric cancer enabled us to realize personalized medicine with targeted agents in gastric cancer treatment.The investigators initiated open-label, randomized, controlled phase II, multi-arm trial comparing targeted therapy based on tumor molecular profiling with standard paclitaxel therapy as second line treatment.

Inclusion criteria

• Histologically or cytologically confirmed locally advanced or metastatic gastric cancer and gastroesophageal junction cancer
• Eastern Cooperative Oncology Group performance status of 0 to 1
• Male or female; ≥ 19 years of age
• On or progression after 1st line palliative chemotherapy
• Subjects with evaluable lesion (using RECIST 1.1 criteria)
• Subjects who meet the following criteria:

• Absolute neutrophil count ≥ 1000 /µL
• Platelet count ≥ 75,000/ µL
• Serum creatinine < 1.5 x upper limit of normal or Creatinine clearance ≥60 mL/min
• aspartate aminotransferase and alanine transaminase 3 x upper limit of normal

Exclusion criteria

• Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study